HUP0500109A2 - 4,5-Dihidro-pirazolo[3,4-c]pirid-2-onok szintézise - Google Patents

4,5-Dihidro-pirazolo[3,4-c]pirid-2-onok szintézise

Info

Publication number
HUP0500109A2
HUP0500109A2 HU0500109A HUP0500109A HUP0500109A2 HU P0500109 A2 HUP0500109 A2 HU P0500109A2 HU 0500109 A HU0500109 A HU 0500109A HU P0500109 A HUP0500109 A HU P0500109A HU P0500109 A2 HUP0500109 A2 HU P0500109A2
Authority
HU
Hungary
Prior art keywords
group
general formula
substituted
oso2ph
phenyl
Prior art date
Application number
HU0500109A
Other languages
English (en)
Inventor
Jiacheng Zhou
Lynette M. Oh
Philip Ma
Hui-Yin Li
Pasquale N. Confalone
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0500109A2 publication Critical patent/HUP0500109A2/hu
Publication of HUP0500109A3 publication Critical patent/HUP0500109A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgya új eljárás általános képletű vegyületek - ahol Dklóratommal, metoxi-, ciano- vagy amino-metil-csoporttal szubsztituáltfenil- vagy benz[d]izoxazolil-csoport; R1 és R2 alkil-, cikloalkil-,fenil- vagy benzilcsoport; R1a hidrogénatom, adott esetbenszubsztituált alkil-, cianocsoport, -CH2OCH3, -CO2CH3, -CH2CO2CH3, -CO2CH2CH3, -CH2CO2CH2CH3, -CH2SCH3, -S(O)CH3, -CH2S(O)CH3, -S(O)2CH3,-CH2S(O)2CH3 képletű, karbamoil-, szulfamoil-, piridil-, N-oxi-piridil-, imidazolil- vagy tetrazolilcsoport; A szubsztituált fenil-,piridil- vagy pirimidinil-csoport B B1 csoport, halogénatom, -OMs, -OTs, -OSO2Ph, -CH2-Br, -CH2-OH, vagy -CHO; vagy A-B hidrogénatom; B1 Yvagy X-Y; X alkiléncsoport, oxigénatom vagy különböző összetettcsoport; Y 3-10 szénatomos szubsztituált karbociklus vagy 5-10 tagúszubsztituált heterociklus - e1őállítására és a szintézis közbensőtermékei. A találmány szerint(I) általános képletű vegyületet - ahol Zhalogénatom, -OSO2Me, -OSO2Ph vagy -OSO2Ph-p-Me- egy (II) általánosképletű vegyülettel reagáltatnak, majd az így kapott (III) általánosképletű vegyületet egy savval reagáltatják. A találmány szerinti 4,5-dihidro-pirazolo[3,4-c]pirid-2-onok Xa faktor inhibitorok. Ó
HU0500109A 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones HUP0500109A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33908501P 2001-12-10 2001-12-10
PCT/US2002/038559 WO2003049681A2 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones

Publications (2)

Publication Number Publication Date
HUP0500109A2 true HUP0500109A2 (hu) 2005-05-30
HUP0500109A3 HUP0500109A3 (en) 2007-08-28

Family

ID=23327425

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500109A HUP0500109A3 (en) 2001-12-10 2002-12-03 Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Country Status (13)

Country Link
US (3) US6919451B2 (hu)
EP (1) EP1467984A4 (hu)
JP (1) JP2005511712A (hu)
KR (1) KR20040073467A (hu)
CN (1) CN1639147A (hu)
AU (1) AU2002346624A1 (hu)
BR (1) BR0214845A (hu)
HU (1) HUP0500109A3 (hu)
IL (1) IL161955A0 (hu)
MX (1) MXPA04005508A (hu)
PL (1) PL371930A1 (hu)
TW (2) TW200303201A (hu)
WO (1) WO2003049681A2 (hu)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20074098B (en) * 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CN101065379B (zh) * 2004-09-28 2011-05-11 布里斯托尔-迈尔斯斯奎布公司 制备4,5-二氢-吡唑并[3,4-c]吡啶-2-酮的方法
US20070203178A1 (en) * 2004-09-28 2007-08-30 Malley Mary F Crystalline solvates of apixaban
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
DE102006025315A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Tetrahydro-pyrrolopyridin-, Tetrahydro-pyrazolopyridin-, Tetrahydro-imidazopyridin- und Tetrahydro-triazolopyridin-Derivate und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032344A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug-Derivate von 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carboxamid
US20090076069A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched apixaban
ES2611657T3 (es) * 2008-09-15 2017-05-09 Auspex Pharmaceuticals, Inc. Inhibidores de pirazol-carboxamida del factor Xa
CN101967145B (zh) * 2010-09-09 2012-07-04 华东理工大学 一种抗血栓药物阿匹沙班的制备方法
ITMI20111047A1 (it) * 2011-06-10 2012-12-11 Dipharma Francis Srl Forma cristallina di apixaban
EP2718262B1 (en) 2011-06-10 2016-08-03 Dipharma Francis S.r.l. Apixaban preparation process
ITMI20111135A1 (it) * 2011-06-22 2012-12-23 Dipharma Francis Srl Procedimento per la preparazione di apixaban
CN103242310A (zh) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途
CN102675314A (zh) * 2012-06-14 2012-09-19 南京正科制药有限公司 一种阿哌沙班的合成方法
CN103626759B (zh) * 2012-08-24 2015-10-21 上海医药工业研究院 一种阿哌沙班的中间体的制备方法
WO2014072884A1 (en) * 2012-11-12 2014-05-15 Alembic Pharmaceuticals Limited Process for the synthesis of apixaban
CZ304846B6 (cs) 2012-11-13 2014-12-03 Zentiva, K.S. Způsob přípravy APIXABANU
US9567332B2 (en) 2013-01-17 2017-02-14 Glenmark Pharmaceuticals Limited Process for the preparation and purification of apixaban
CN103539795A (zh) * 2013-03-18 2014-01-29 齐鲁制药有限公司 阿哌沙班的多晶型及其制备方法
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
US20160113912A1 (en) 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN103739541B (zh) * 2014-01-07 2016-01-20 上海现代制药股份有限公司 5,6-二氢-3-(4-吗啉基)-1-[4-(2-氧代-1-哌啶基)苯基]-2(1h)-吡啶酮的制备方法
IN2014MU00197A (hu) 2014-01-21 2015-08-28 Wanbury Ltd
CN103896940B (zh) * 2014-03-25 2016-02-03 江苏弘和药物研发有限公司 一种阿哌沙班的合成方法
CN103923080B (zh) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 一种制备抗血栓药物阿哌沙班的方法
CN104045637B (zh) * 2014-04-18 2016-04-06 河北科技大学 一种阿哌沙班的制备方法
WO2015162551A1 (en) 2014-04-21 2015-10-29 Mylan Laboratories Ltd Process for the preparation of apixaban
EP3147283B1 (en) * 2014-05-22 2022-08-17 North China Pharmaceutical Company., Ltd. Hydrazine compound as blood coagulation factor xa inhibitor
WO2015177801A1 (en) * 2014-05-23 2015-11-26 Symed Labs Limited Novel process for the preparation of a lactam-containing compound
HU231122B1 (hu) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Eljárás apixaban előállítására
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CN104277037B (zh) * 2014-09-19 2015-12-09 广东东阳光药业有限公司 含有螺环的吡唑并哌啶酮类化合物及其组合物及用途
CN104311555B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
CN104327074B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有内酰胺取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277040B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有酰基哌嗪酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311558B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有环己烷取代基的吡唑并哌啶酮类化合物及其组合物及用途
EP3098221B1 (en) * 2014-10-15 2017-12-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing apixaban form n-1
US9932336B2 (en) 2014-10-28 2018-04-03 Jubilant Generics Limited Process for the preparation of apixaban and intermediates thereof
HU230991B1 (hu) 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Eljárás és köztitermék apixaban előállítására
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
CN104892601B (zh) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 一种抗血栓药物阿哌沙班的制备方法
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
CN106632312B (zh) * 2015-11-03 2019-05-14 上海医药工业研究院 一种阿哌沙班有关物质、中间体、制备方法及其应用
CN105732618A (zh) * 2016-02-02 2016-07-06 扬州大学 一种合成4-(2-氧代哌啶-1-基)芳基羧酸乙酯类化合物的方法
PL3228619T3 (pl) * 2016-04-04 2020-12-28 Zakłady Farmaceutyczne Polpharma Sa Sposób wytwarzania apiksabanu
US10077263B2 (en) 2016-04-29 2018-09-18 Optimus Drugs Private Limited Process for the preparation of Apixaban
CN106117200B (zh) * 2016-06-27 2018-02-02 张士伟 预防或治疗关节置换静脉血栓药物阿哌沙班的制备方法
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
CN107434806A (zh) * 2016-12-09 2017-12-05 陕西科技大学 一种阿哌沙班羧酸衍生物的γ晶型固体物质及其制备方法与用途
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
CN107955002B (zh) * 2017-12-27 2019-12-24 上海博志研新药物技术有限公司 阿哌沙班及其中间体的制备方法
CN107936015B (zh) * 2017-12-28 2020-05-12 浙江天宇药业股份有限公司 一种n-1晶型的阿哌沙班的合成方法
CN107955003A (zh) * 2017-12-28 2018-04-24 河北常山生化药业股份有限公司 一种阿哌沙班中间体2合成过程中特定杂质s4的清除方法
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
KR102188341B1 (ko) 2018-10-24 2020-12-08 하나제약 주식회사 아픽사반의 제조방법
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
CN111253392B (zh) * 2019-12-17 2021-06-11 哈尔滨珍宝制药有限公司 一种制备阿哌沙班的方法
CN113214142B (zh) * 2020-01-21 2024-01-30 浙江九洲药业股份有限公司 一种阿哌沙班的中间体及制备方法
JP2022022550A (ja) * 2020-06-26 2022-02-07 ダイト株式会社 アピキサバンの新規製造方法
CN112142736B (zh) * 2020-10-29 2021-08-10 怀化学院 一种阿哌沙班杂质1的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459240A1 (fr) 1979-06-21 1981-01-09 Cm Ind Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent
ES2232202T3 (es) * 1998-12-23 2005-05-16 Bristol-Myers Squibb Pharma Company Heterobiciclos que contienen nitrogeno como inhibidores del factor xa.
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GEP20074098B (en) * 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
IL161955A0 (en) 2005-11-20
US6919451B2 (en) 2005-07-19
PL371930A1 (en) 2005-07-11
US20030181466A1 (en) 2003-09-25
KR20040073467A (ko) 2004-08-19
HUP0500109A3 (en) 2007-08-28
EP1467984A4 (en) 2005-12-07
TW200303201A (en) 2003-09-01
AU2002346624A1 (en) 2003-06-23
US7153960B2 (en) 2006-12-26
MXPA04005508A (es) 2004-12-06
CN1639147A (zh) 2005-07-13
BR0214845A (pt) 2004-12-07
TW200738672A (en) 2007-10-16
JP2005511712A (ja) 2005-04-28
US20070027186A1 (en) 2007-02-01
WO2003049681A2 (en) 2003-06-19
US20050245566A1 (en) 2005-11-03
EP1467984A2 (en) 2004-10-20
WO2003049681A3 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
HUP0500109A2 (hu) 4,5-Dihidro-pirazolo[3,4-c]pirid-2-onok szintézise
ATE18910T1 (de) Succinimid-derivate und verfahren zu ihrer herstellung.
TW200519085A (en) Chemical compounds
NZ526470A (en) Pyrazole compounds useful as protein kinase inhibitors
NO20050065L (no) Kjemiske forbindelser
GB9803226D0 (en) Chemical compounds
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
WO2004024777A8 (en) Hydroxyalkyl starch derivatives
NO20071707L (no) Fremstilling av 4,5-dihydro-pyrazolo[3,4-C]Pyrid-2-oner
ATE548375T1 (de) Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
MXPA03000235A (es) Preparacion de derivados 4-tioalquilbromobenceno.
ATE386083T1 (de) Oberflächenbelegte perlglanzpigmente, verfahren zu deren herstellung und deren verwendung
SI1539796T1 (sl) Protivnetni ali protialergični androstanski kompleksi
MX2007003427A (es) Sintesis eficiente de 4,5-dihidro-pirazolo[3,4-c]pirid-2-onas.
MY138051A (en) Compounds and processes
TW200619201A (en) Process for the preparation of pyrazoles
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
DE60330152D1 (de) Verfahren zur herstellung von nitrooxyderivaten von naproxen
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
AP2001002194A0 (en) Novel process for the preparation of pyrazolopyrimidinones.
AU2003224115A1 (en) A process for the preparation of clopidogrel
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
EP0559116A3 (en) Microbiological process for the hydroxylation of nitrogen containing heterocyclic carbonic acids
UA98834C2 (ru) 19-НОР-СТЕРОИДНЫЕ ПРОИЗВОДНЫЕ С 15α,16α-МЕТИЛЕНОВОЙ ГРУППОЙ И НАСЫЩЕННЫМ 17,17-СПИРОЛАКТОНОВЫМ КОЛЬЦОМ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, КОТОРОЕ СОДЕРЖИТ ЭТИ ПРОИЗВОДНЫЕ
DE60317487D1 (de) Verfahren zur herstellung von 2,6-dihalogenpurin

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees